Xbrane Biopharma has celebrated after being granted two Swedish patents covering its “high-yield” protein expression platform that the biosimilars specialist expects to act as the basis for international applications.

Sweden’s Xbrane Biopharma has secured a manufacturing partner in its native Scandinavia, Denmark’s AGC Biologics, to help complete key steps for its proposed Xcimzane (certolizumab pegol) biosimilar to Cimzia ahead of Phase I and Phase III clinical trials.

Xbrane Biopharma has taken a key step on its journey to begin generating cash from operations by early 2024 at the latest, after its Xlucane biosimilar ranibizumab asset was submitted to the European Medicines Agency by co-development and commercialization partner Stada.

With ambitions to file biosimilar ranibizumab and initiate one new development program per year, Sweden’s Xbrane Biopharma has brought in millions of much needed fresh capital to fuel operations.